Pediatric Cancer
Conditions
Brief summary
PanCareLIFE Study is a cohort study of patients treated for cancer in childhood, and biological case-control study nested in the cohort (WP4) is coordinated by Erasmus MC-Sophia Children's Hospital in Holland. Ensure optimal patient quality of life throughout his life is a priority for the research teams. PanCareLIFE Study also aims to identify the factors that predispose to impaired quality of life. It is in this light that will be offered to patients a quality of life questionnaires during the period of treatment and then periodically during long-term follow-up.
Detailed description
PanCareLIFE Study is a cohort study of patients treated for cancer in childhood, and biological case-control study nested in the cohort (WP4) is coordinated by Erasmus MC-Sophia Children's Hospital in Holland. At European level, approximately 1,200 women are expected in this latest study, the patients were already identified through certain regional or national registries in terms of cumulative doses of chemotherapy, surgery, radiation. Ensure optimal patient quality of life throughout his life is a priority for the research teams. PanCareLIFE Study also aims to identify the factors that predispose to impaired quality of life. It is in this light that will be offered to former patients to complete quality of life questionnaires during the period of treatment and then periodically during long-term follow-up. The SALTO-BIO study is the French part of the European study PanCareLIFE. CHU of Saint-Etienne as French promotor, will organize this study only on the Rhône-Alpes region (Lyon, Grenoble and Saint-Etienne centers) and will participate as co-investigator and data provider to WP2, WP3, WP4 and WP6. Indeed, ototoxicity is already studied by a French group.
Interventions
OTHERPediatric cancer women survivors
Women will incur a blood taking to obtain fertility indication.
Sponsors
Centre Hospitalier Universitaire de Saint Etienne
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* min 18 years old * female * diagnosed for a cancer between 01/01/87 and 31/12/99, before 15 years old, and living in Rhône-Alpes * treated with chemotherapy +/- radiotherapy * accepting a blood taking to perform DNA and hormonal tests * affiliated to a security social scheme * informed consent
Exclusion criteria
\- severe mental disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure the FSH hormone rate. | Day 1 | In this arm women will incur a blood taking to measure the FSH hormone rate. |
| Measure the AMH hormone rate. | Day 1 | In this arm women will incur a blood taking to measure the AMH hormone rate. |
| Detect the genetic polymorphism of the FSH and AMH hormones. | Day 1 | With the blood taking realized for each patient, genetic markers will be obtained to identify their fertility capacity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life | Day 1 | The quality of life for each patient will be measured with the SF-36 scale. |
| Identification of new loci associated to ovarian toxicity | Day 1 | With a pan-genomic method, new loci (associated to ovarian toxicity) will be identified. |
Countries
France
Outcome results
None listed